AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 149.58M | -75.35000M | -42.32200M | -94.81100M | -142.70500M |
| Minority interest | - | - | - | - | - |
| Net income | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Selling general administrative | 403.71M | 354.30M | 334.30M | 680.92M | 604.35M |
| Selling and marketing expenses | 450.30M | 405.10M | 403.40M | - | - |
| Gross profit | 1612.37M | 1375.76M | 1336.18M | 1344.58M | 1175.95M |
| Reconciled depreciation | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M |
| Ebit | 57.55M | -60.01300M | -96.26000M | -125.45700M | -149.04100M |
| Ebitda | 159.51M | 48.03M | -5.85000M | -22.24300M | -100.25000M |
| Depreciation and amortization | 101.97M | 108.04M | 90.41M | 103.21M | 48.79M |
| Non operating income net other | - | 10.48M | 16.60M | 22.16M | 22.28M |
| Operating income | 57.55M | -60.01300M | -96.26000M | -125.45700M | -123.52400M |
| Other operating expenses | 2054.48M | 1928.62M | 1956.71M | 1829.51M | 1664.74M |
| Interest expense | 15.97M | 15.34M | 29.31M | 23.46M | 43.66M |
| Tax provision | 8.02M | -11.27000M | -901.42200M | -70.96300M | -65.49400M |
| Interest income | 18.03M | 10.48M | 16.61M | 22.75M | 22.83M |
| Net interest income | 2.06M | -4.85500M | -12.69900M | -0.71200M | -20.83300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 8.02M | -11.27000M | -901.42200M | -70.96300M | -65.49400M |
| Total revenue | 2096.04M | 1846.28M | 1860.45M | 1704.05M | 1491.21M |
| Total operating expenses | 1570.81M | 1458.10M | 1432.44M | 1470.04M | 1349.47M |
| Cost of revenue | 483.67M | 470.51M | 524.27M | 359.47M | 315.26M |
| Total other income expense net | 92.03M | -15.33700M | 53.94M | 30.65M | 51.65M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Net income applicable to common shares | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 6375.07M | 6003.32M | 5848.02M | 4690.04M | 4427.13M |
| Intangible assets | 338.57M | 388.65M | 417.27M | 456.58M | 491.81M |
| Earning assets | - | - | - | - | - |
| Other current assets | 104.52M | 110.44M | 129.93M | 130.66M | 98.40M |
| Total liab | 1771.92M | 1732.59M | 1742.02M | 1567.66M | 1459.19M |
| Total stockholder equity | 4603.16M | 4270.74M | 4106.00M | 3122.38M | 2967.94M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 346.56M | 329.40M | 289.21M | -13.03700M | 85.95M |
| Common stock | 0.19M | 0.18M | 0.18M | 0.18M | 0.18M |
| Capital stock | 0.19M | 0.18M | 0.18M | 0.18M | 0.18M |
| Retained earnings | -789.19900M | -925.68900M | -861.60900M | -1720.70900M | -1694.13400M |
| Other liab | 73.50M | 113.69M | 174.32M | 98.12M | 105.53M |
| Good will | 196.20M | 196.20M | 196.20M | 197.04M | 197.04M |
| Other assets | 1604.19M | 1600.84M | 1574.39M | 612.00M | 496.58M |
| Cash | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 588.88M | 539.82M | 492.55M | 932.50M | 523.24M |
| Current deferred revenue | 0.71M | 6.96M | 0.15M | 13.04M | - |
| Net debt | 358.49M | 491.80M | 425.99M | 410.67M | 336.44M |
| Short term debt | 10.38M | 10.46M | 11.75M | 361.88M | - |
| Short long term debt | - | - | - | 361.88M | - |
| Short long term debt total | 1083.02M | 1079.08M | 1075.14M | 848.12M | 830.42M |
| Other stockholder equity | 5396.04M | 5181.81M | 4983.57M | 4822.75M | 4656.62M |
| Property plant equipment | 1114.32M | 1035.46M | 1032.47M | 1010.87M | 948.68M |
| Total current assets | 2751.46M | 2274.39M | 2342.22M | 1942.14M | 2056.22M |
| Long term investments | 333.83M | 507.79M | 285.47M | 411.98M | 235.86M |
| Net tangible assets | 4068.39M | 3685.89M | 3492.53M | 2468.76M | 2279.09M |
| Short term investments | 567.01M | 426.60M | 416.23M | 316.36M | 590.33M |
| Net receivables | 461.32M | 373.40M | 448.35M | 377.40M | 342.63M |
| Long term debt | 1083.02M | 1079.08M | 1075.14M | 486.24M | 830.42M |
| Inventory | 894.08M | 776.67M | 698.55M | 680.27M | 530.87M |
| Accounts payable | 231.24M | 193.00M | 191.43M | 570.62M | 437.29M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.86700M | 14.43M | -16.13900M | 20.16M | 5.27M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.18M | 0.18M | 0.18M | 0.18M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -925.68900M | -861.60900M | -1720.70900M | -1694.13400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 176.24M | 151.76M | 142.24M | 122.01M | 36.57M |
| Deferred long term asset charges | - | - | - | - | 460.95M |
| Non current assets total | 3623.62M | 3728.94M | 3505.80M | 2747.90M | 2370.91M |
| Capital lease obligations | 10.38M | 10.46M | 11.75M | 10.70M | - |
| Long term debt total | - | 1079.08M | 1075.14M | 486.24M | 830.42M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -20.02900M | -366.31300M | 26.17M | 108.19M | 358.98M |
| Change to liabilities | 59.02M | 12.35M | -93.89600M | 80.22M | 47.30M |
| Total cashflows from investing activities | -20.02900M | -366.31300M | -53.62100M | -31.02600M | 264.35M |
| Net borrowings | -2.60500M | -3.03900M | 210.76M | -5.08700M | -374.95300M |
| Total cash from financing activities | -18.65000M | -0.04800M | 181.12M | -74.67400M | -388.00700M |
| Change to operating activities | -5.10400M | 19.83M | -17.20600M | -32.77500M | -9.78800M |
| Net income | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Change in cash | 137.25M | -61.88200M | 211.71M | -56.53600M | -104.04600M |
| Begin period cash flow | 587.28M | 649.16M | 437.45M | 493.98M | 598.03M |
| End period cash flow | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M |
| Total cash from operating activities | 175.90M | 304.54M | 85.36M | 48.26M | 20.21M |
| Issuance of capital stock | - | - | - | - | 0.00000M |
| Depreciation | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M |
| Other cashflows from investing activities | 103.33M | -24.64100M | 34.52M | 5.81M | 49.99M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -68.26400M | -35.06000M | -61.15100M | -107.55400M | -23.74700M |
| Change to account receivables | -82.03300M | 65.57M | -59.03500M | -37.85200M | -54.27400M |
| Sale purchase of stock | 0.00000M | 49.19M | -50.00000M | 31.61M | 67.49M |
| Other cashflows from financing activities | -16.04500M | 2.99M | 613.03M | -69.58700M | -13.05400M |
| Change to netincome | 28.75M | 185.24M | -671.56800M | 56.66M | 19.62M |
| Capital expenditures | 131.54M | 119.22M | 137.52M | 163.41M | 144.62M |
| Change receivables | - | 65.57M | -59.03500M | -37.85200M | -54.27400M |
| Cash flows other operating | - | 23.17M | -10.33500M | -36.61700M | -18.70200M |
| Exchange rate changes | - | -0.05700M | -1.15000M | 0.90M | -0.59800M |
| Cash and cash equivalents changes | - | -61.88200M | 211.71M | -56.53600M | -104.04600M |
| Change in working capital | -96.38300M | 66.03M | -224.41700M | -101.09200M | -49.42000M |
| Stock based compensation | 196.31M | 197.26M | 189.71M | 159.87M | 148.82M |
| Other non cash items | -115.46600M | 12.89M | 44.71M | -9.20300M | -29.27300M |
| Free cash flow | 44.36M | 185.31M | -52.15400M | -115.14400M | -124.41200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMRN Biomarin Pharmaceutical Inc |
-9.03 9.90% | 82.17 | 124.95 | 34.01 | 7.55 | 3.56 | 7.54 | 65.01 |
| NVO Novo Nordisk A/S |
-0.37 0.29% | 125.79 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-3.3 2.60% | 123.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.06 0.76% | 397.70 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.06 0.07% | 90.16 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
770 Lindaro Street, San Rafael, CA, United States, 94901
| Name | Title | Year Born |
|---|---|---|
| Mr. Jean-Jacques Bienaime M.B.A., MBA | Chairman & CEO | 1953 |
| Mr. Brian R. Mueller | Exec. VP of Fin. & CFO | 1974 |
| Dr. C. Greg Guyer Ph.D. | CTO and Exec. VP of Global Manufacturing & Technical Operations | 1962 |
| Mr. Jeffrey Robert Ajer | Exec. VP & Chief Commercial Officer | 1962 |
| Dr. Henry J. Fuchs M.D., Ph.D. | Pres of Worldwide R&D | 1958 |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | NA |
| Traci McCarty | VP of Investor Relations | NA |
| Mr. George Eric Davis | Exec. VP, Gen. Counsel & Sec. | 1971 |
| Mr. Philip Lo Scalzo | Sr. VP & Chief Compliance Officer | NA |
| Ms. Humaira Serajuddin | Sr. VP & Chief Marketing Officer | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...